Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14351 - 14375 of 14516 in total

4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID

Experimental

1-(4-Cyano-phenyl)-3-[2-(2,6-dichloro-phenyl)-1-imino-ethyl]-thiourea

Experimental

BUT-3-ENYL-[5-(4-CHLORO-PHENYL)-3,6-DIHYDRO-[1,3,4]THIADIAZIN-2-YLIDENE]-AMINE

Experimental

3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile

Experimental

phenyl ethenesulfonate

Experimental

WIN-54954

WIN-54954 is a broad-spectrum antipicornavirus drug.
Experimental

Tulobuterol

Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational

Mavatrep

Mavatrep has been used in trials studying the treatment of Osteoarthritis, Knee.
Investigational

LY-2300559

Ly2300559 has been used in trials studying the prevention of Migraine Headache.
Investigational

Benzododecinium

Benzododecinium is used as an antiseptic/disinfectant compound. It has been marketed as a tincture for antiseptic product for wounds in the Czech Republic.
Experimental

Guanoxabenz

Experimental

Pridinol

Experimental

Fenoxazoline

Experimental

Myristalkonium

Experimental

Bibrocathol

Experimental

N-Alkyl dimethyl benzyl ammonium chloride (C12-C18)

Experimental

4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN

Experimental

4-[4-AMINO-6-(2,6-DICHLORO-PHENOXY)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE

Experimental

DG051

DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and …

2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE

Experimental

T-62

T-62 has been used in trials studying the treatment of Postherpetic Neuralgia.
Investigational

MCC

Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing...
Investigational
Matched Description: … MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against …

ATX-201

ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …

(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide

(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes. These are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A.
Experimental
Matched Description: … containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and …

2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL

Experimental
Displaying drugs 14351 - 14375 of 14516 in total